The clinic will be able to accommodate 1,500 patients over a long period and 50 patients with a left ventricular assist ...

Using nearly a decade of data (2015–2023) from 800+ U.S. hospitals and more than 700,000 patients overall, Northwestern ...

A novel approach to removing excess fluid through the skin and a new strategy to prevent right ventricular failure after LVAD implantation are among the highlights of the January issue of the Journal ...

Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...

The updated guidelines recommend that people keep their systolic blood pressure under a specific number — 130 — to prevent ...

Early initiation of an intensive blood pressure control reduced the risk for MACE among older patients with hypertension.

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...

Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing, along with the aging population and the ongoing rise in risk factors such as hypertension, ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.